GP6 and coronary artery disorder: GPVI is also a novel antiplatelet target for the treatment of inflammatory disorders including CAD (reviewed in36,38,39), and levels of membrane bound and soluble GPVI predict outcomes after myocardial infarction and stroke (reviewed in40).